title: Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010.
abstract: Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a cephalosporin with in vitro bactericidal activity against Gram-positive organisms, including methicillin-susceptible and -resistant Staphylococcus aureus, β-haemolytic and viridans group streptococci, and Streptococcus pneumoniae, as well as common Gram-negative organisms. In this study a total of 986 isolates collected in 2010 from patients in 15 medical centers in five Latin American countries from the Assessing Worldwide Antimicrobial Resistance Evaluation Program were identified as community-acquired respiratory tract or skin and soft tissue infection pathogens. Ceftaroline was the most potent agent tested against S. pneumoniae with a MIC90 value (0.12μg/mL) that was eight-fold lower than ceftriaxone, levofloxacin, and linezolid. Its spectrum of coverage (100.0% susceptible) was similar to tigecycline, linezolid, levofloxacin and vancomycin. Against Haemophilus influenzae and Moraxella catarrhalis, ceftaroline was the most active agent tested. The activity of ceftaroline against S. aureus (including MRSA) was similar to that of vancomycin and tetracycline (MIC90, 1μg/mL) and linezolid (MIC90, 2μg/mL). The β-haemolytic streptococci exhibited 100.0% susceptibility to ceftaroline. Ceftaroline activity against Escherichia coli, Klebsiella spp., and Enterobacter spp. was similar to that of ceftriaxone and ceftazidime. These parenteral cephalosporin agents have potent activity against non-extended-spectrum β-lactamase-phenotype strains, but are not active against extended-spectrum β-lactamase-phenotype strains. These results confirm the in vitro activity of ceftaroline against pathogens common in community-acquired respiratory tract and skin and soft tissue infection in Latin America, and suggest that ceftaroline fosamil could be an important therapeutic option for these infections.
authors.affiliation: JMI Laboratories, North Liberty, IA, USA. Electronic address: robert-flamm@jmilabs.com.
authors.forename: Robert K
authors.initials: RK
authors.lastname: Flamm
authors.forename: Helio S
authors.initials: HS
authors.lastname: Sader
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Jones
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D006090:Gram-Negative Bacteria / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D007843:Latin America; D008826:Microbial Sensitivity Tests; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology; D017192:Skin Diseases, Bacterial / Q000188:drug therapy / Q000382:microbiology; D018461:Soft Tissue Infections / Q000188:drug therapy / Q000382:microbiology; D000097583:Ceftaroline
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000097583:Ceftaroline
keywords: AWARE; Ceftaroline; S. aureus; S. pneumoniae
references.citation: J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii69-80
references.pmid: 21482572
references.citation: J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii45-51
references.pmid: 21482569
references.citation: Clin Infect Dis. 2010 Sep 15;51(6):641-50
references.pmid: 20695801
references.citation: J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv41-51
references.pmid: 21115454
references.citation: J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii11-8
references.pmid: 21482565
references.citation: Antimicrob Agents Chemother. 2012 Jun;56(6):2933-40
references.pmid: 22470115
references.citation: J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv9-16
references.pmid: 21115457
references.citation: Clin Infect Dis. 2012 Sep;55 Suppl 3:S181-6
references.pmid: 22903950
references.citation: J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv33-9
references.pmid: 21115453
references.citation: J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv3-8
references.pmid: 21115452
references.citation: Diagn Microbiol Infect Dis. 2010 Nov;68(3):334-6
references.pmid: 20955919
references.citation: Clin Microbiol Infect. 2006 May;12 Suppl 3:31-41
references.pmid: 16669927
references.citation: Clin Infect Dis. 2012 Sep;55 Suppl 3:S206-14
references.pmid: 22903953
references.citation: Clin Infect Dis. 2012 Sep;55 Suppl 3:S187-93
references.pmid: 22903951
references.citation: J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv53-iv65
references.pmid: 21115455
references.citation: Postgrad Med. 2010 Mar;122(2):130-41
references.pmid: 20203464
references.citation: J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv17-31
references.pmid: 21115451
references.citation: Emerg Infect Dis. 2006 Nov;12(11):1715-23
references.pmid: 17283622